Atorvastatin for Renoprotective Effects in contrast-induced NephropAthy prevention

Atorvastatin for Renoprotective Effects in Contrast-induced Nephropathy Prevention

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180816001

Enrollment

257

Registered

2018-08-16

Start date

2018-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney disease stage 3&#45

Interventions

80 mg 2 days prior to coronary angiography,Placebo 2 days prior to coronary angiography

Experimental Drug,Placebo Comparator Drug

Atorvastatin,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - 18-80 years old - Undergoing elective coronary angiography - eGFR (within 3 months) 15-60 mL/min/1.73 m2

Exclusion criteria

Exclusion criteria: - Acute coronary syndrome - Have an indication for high-dose statin e.g. coronary artery disease, cerebrovascular disease - AST or ALT > 3 times of normal limits - CPK > 500 U/L

Design outcomes

Primary

Measure	Time frame
Contrast-induced nephropathy 72 hours Serum creatinine	—

Secondary

Measure	Time frame
Change in urine NGAL 6 hours Urine NGAL	—

Contacts

Public ContactPaweena Susantitaphong

Faculty

pesancerinus@hotmail.com66-86-413-7885

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Atorvastatin for Renoprotective Effects in contrast&#45;induced NephropAthy prevention